Drug Profile
Pasireotide long-acting formulation - Camurus
Alternative Names: CAM-4071Latest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Camurus
- Class Analgesics; Antineoplastics; Antisecretories; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptides; Peptidomimetics
- Mechanism of Action Corticotropin releasing hormone inhibitors; Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Endocrine disorders
Most Recent Events
- 19 Oct 2022 Phase I development is still ongoing for Endocrine disorders in Europe (Camurus pipeline, October 2022)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Endocrine-disorders(In volunteers) in Europe (SC, Controlled release)
- 09 Apr 2020 Phase I development is still ongoing for Endocrine disorders in Europe (Camurus pipeline, April 2020)